GenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL

Bulletin Express

06/02

GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).

Legend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.

To support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.

GenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1176047743"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176047743\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176047743?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176047743","market":"us","top_or_hot":-1,"title":"GenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL","media":"Bulletin Express","content":"<p>GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).</p>\n<p>Legend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.</p>\n<p>To support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.</p>\n<p>GenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).</p>\n<p>Legend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.</p>\n<p>To support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.</p>\n<p>GenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1176047743","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176047743","pubTimestamp":1780411453,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物科技(GenScript Biotech)的合作伙伴传奇生物科技(Legend Biotech)计划在EHA 2026上发布最新的口服药物，以揭示LB2501治疗R/R B-NHL的初始1期体内CAR-T数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).\nLegend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.\nTo support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.\nGenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}